Leukemia & Lymphoma | 2020
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: Long term follow up of a novel high dose regimen.
Hagen P, D'Souza A, Hari P, Davila O, Zhang M-J, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ
PubMed
PMID: 32865474
Abstract
Related Articles
CIBMTR Study #: MM18-04